Benlysta (belimumab) is a prescription medication used to treat active systemic lupus erythematosus (SLE) and active lupus nephritis. It can be given as an intravenous (IV) infusion or an injection ...

Benlysta is a human monoclonal antibody that was approved for the treatment of lupus in adults by the U.S. Food and Drug Administration (FDA) in 2011 and for lupus nephritis in adults in 2020.

Benlysta is a brand-name prescription drug that’s used to help manage certain types of lupus in adults and some children. Here are key things to know about this medication and how to take it safely ...

The U.S. Food and Drug Administration has approved GSK's autoinjector of Benlysta (belimumab) for subcutaneous injection in patients ≥5 years of age with active lupus nephritis who are receiving ...

The European Commission has approved a new subcutaneous formulation of belimumab (Benlysta, GlaxoSmithKline) as adjunctive treatment for adults with active, autoantibody-positive systemic lupus ...

The approval makes belimumab (Benlysta) the first at-home treatment in its class for patients 5 years and older with systemic lupus erythematosus (SLE). The FDA approved GSK’s belimumab (Benlysta) ...

The FDA has expanded the approval of belimumab to include pediatric patients 5 to 17 years of age with active lupus nephritis. The Food and Drug Administration (FDA) has expanded the approval of ...

In adults and children five years and up Benlysta can be administered by a medical professional through an IV (intravenous) infusion directly into the vein; adults can self-administer an injection ...

The Food and Drug Administration (FDA) has expanded the approval of Benlysta (belimumab) to include pediatric patients 5 to 17 years of age with active lupus nephritis who are receiving standard ...